Literature DB >> 16864942

Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension.

Herre J Reesink1, Ronald C Meijer, René Lutter, Frans Boomsma, Henk M Jansen, Jaap J Kloek, Paul Bresser.   

Abstract

BACKGROUND: In non-thromboembolic pulmonary hypertension, endothelin (ET)-1 levels are increased and correlate with the hemodynamic severity of the disease. Whether such correlations exist in chronic thromboembolic pulmonary hypertension (CTEPH) is unknown, nor whether ET-1 levels correlate with hemodynamic outcome after pulmonary endarterectomy (PEA). METHODS AND
RESULTS: ET-1 levels were determined by ELISA. ET-levels were increased in 35 CTEPH patients (1.62+/-0.21 pg/ml) compared with healthy controls (n=11: 0.75+/-0.06 pg/ml, p<0.02). ET-1 levels correlated (all p<0.0001) with mean pulmonary artery pressure (mPAP) (r=0.70), cardiac index (r=-0.76), total pulmonary resistance (r=0.72), mixed venous oxygen saturation (r=-0.87), and the distance walked in the 6-min walk test (r=-0.59; p<0.005; n=23). Three months after PEA, ET-1 levels had decreased (p<0.002), and were similar between patients with and without residual pulmonary hypertension (p=0.4). Preoperative ET-1 levels, however, were higher in patients with bad postoperative outcome; that is, patients who either died because of persistent pulmonary hypertension or had residual pulmonary hypertension after PEA (2.68+/-0.48 pg/ml, and 1.13+/-0.15 pg/ml, respectively; p<0.002). The levels also correlated with hemodynamic outcome after PEA (mPAP: r=0.67, p<0.0001). By receiver-operator characteristic curve analysis, ET-1>1.77 pg/ml detected a bad postoperative outcome with a sensitivity and specificity of 79% and 85%, respectively, and a likelihood ratio of 5.2.
CONCLUSION: ET-1 levels in CTEPH closely correlated with the hemodynamic and clinical severity of disease in a large cohort of patients. Preoperative ET-1 levels may be useful for better identification of patients at risk for persistent pulmonary hypertension after PEA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864942     DOI: 10.1253/circj.70.1058

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  22 in total

Review 1.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

2.  Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and disease severity.

Authors:  Roberta L Keller; Theresa A Tacy; Karen Hendricks-Munoz; Jie Xu; Anita J Moon-Grady; John Neuhaus; Phillip Moore; Kerilyn K Nobuhara; Sam Hawgood; Jeffrey R Fineman
Journal:  Am J Respir Crit Care Med       Date:  2010-04-22       Impact factor: 21.405

3.  Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  M C Post; H W M Plokker; J C Kelder; R J Snijder
Journal:  Neth Heart J       Date:  2009-09       Impact factor: 2.380

4.  Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Magdalena L Bochenek; Christiane Leidinger; Nico S Rosinus; Rajinikanth Gogiraju; Stefan Guth; Lukas Hobohm; Kerstin Jurk; Eckhard Mayer; Thomas Münzel; Mareike Lankeit; Markus Bosmann; Stavros Konstantinides; Katrin Schäfer
Journal:  Circ Res       Date:  2019-11-21       Impact factor: 17.367

5.  MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.

Authors:  Martin Kolditz; Hans-Jürgen Seyfarth; Heinrike Wilkens; Ralf Ewert; Tom Bollmann; Christiane Dinter; Sabine Hertel; Hans Klose; Christian Opitz; Ekkehard Grünig; Gert Höffken; Michael Halank
Journal:  Lung       Date:  2015-09-12       Impact factor: 2.584

6.  Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.

Authors:  Sulaiman Surie; Herre J Reesink; J Tim Marcus; Mart N van der Plas; Jaap J Kloek; Anton Vonk-Noordegraaf; Paul Bresser
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

7.  Subclinical Atherosclerosis in Patients with Prior Pulmonary Thromboembolism.

Authors:  Zafer Buyukterzi; Meral Buyukterzi; Ercan Kurtipek; Mehmet Sertac Alpaydin; Sukru Karaarslan
Journal:  Med Princ Pract       Date:  2017-04-04       Impact factor: 1.927

8.  Differentially expressed plasma microRNAs and the potential regulatory function of Let-7b in chronic thromboembolic pulmonary hypertension.

Authors:  Lijuan Guo; Yuanhua Yang; Jie Liu; Lei Wang; Jifeng Li; Ying Wang; Yan Liu; Song Gu; Huili Gan; Jun Cai; Jason X-J Yuan; Jun Wang; Chen Wang
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

9.  High preoperative plasma endothelin-1 levels are associated with increased acute kidney injury risk after pulmonary endarterectomy.

Authors:  Fabrizio Grosjean; Mara De Amici; Catherine Klersy; Gianluca Marchi; Antonio Sciortino; Federica Spaltini; Maurizio Pin; Valentina Grazioli; Anna Celentano; Benedetta Vanini; Giorgia Testa; Vincenzo Sepe; Teresa Rampino; Andrea Maria D'Armini
Journal:  J Nephrol       Date:  2018-09-18       Impact factor: 3.902

10.  Chronic Thromboembolic Pulmonary Hypertension Medical Management.

Authors:  Ryan Logue; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.